文献速递血管炎

癌症免疫检查点抑制剂治疗相关血管炎作为免疫相关不良事件的范围综述:揭示免疫学与血管病理学交叉处的复杂性

A scoping review of vasculitis as an immune-related adverse event from checkpoint inhibitor therapy of cancer: Unraveling the complexities at the intersection of immunology and vascular pathology.
PubMed 文献 · Semin Arthritis Rheum · 2024-03-27

该范围综述遵循PRISMA-ScR框架,检索PUBMED后纳入24篇文献中的29例免疫检查点抑制剂(ICI)相关血管炎病例。患者平均年龄62.1±11.0岁,以肺癌和黑色素瘤为主,平均用药8.7±10.5周期后7.2±7.8个月起病,96%使用糖皮质激素,86.2%临床改善。作者认为该事件罕见且异质,起病延迟,结局总体良好,亟需标准化报告。

要点

  • ICI相关血管炎罕见且临床异质,多数在开始免疫治疗后延迟起病(平均7.2±7.8个月)。
  • 96%病例使用糖皮质激素治疗,86.2%(n=25)记录到临床改善。
  • 仅8例符合2022 ACR/EULAR血管炎分类标准,按Chapel-Hill命名约三分之一为小血管炎。

核心结论

  • ICI相关血管炎临床表现异质且罕见,在记录充分的病例中呈免疫治疗启动后延迟起病。
  • ICI相关血管炎的结局总体良好,对糖皮质激素和停用免疫治疗有反应。
  • 亟需对血管炎等罕见irAE进行更标准化的报告,以明确临床风险、分类、与免疫治疗的关系及结局。

研究设计与样本

  • 采用PRISMA-ScR框架的范围综述,于2022年9月和11月进行两次独立PUBMED检索。
  • 共发现127篇文献,按标题排除37篇、按文章类型排除43篇、因缺乏活检结果或活检血管炎阴性排除23篇。
  • 最终纳入24篇文献中的29例记录病例,收集人口学、ICI详情、血管炎症状起病时间、irAE治疗和结局。
  • 血管炎分类采用2022 ACR/EULAR血管炎分类标准及2012修订版Chapel-Hill命名,并借鉴Naidoo等2023年irAE共识定义区分激素敏感与不敏感。

主要发现

  • 29例患者平均年龄62.1±11.0岁,男性58.6%(n=17)、女性41.3%(n=12)。
  • 主要癌种为肺癌41.4%(n=12)、黑色素瘤41.4%(n=12)、肾癌10.3%(n=3),多数为4期75.9%(n=22)和3期10.3%(n=3)。
  • 仅8例符合ACR/EULAR标准;按Chapel-Hill命名约三分之一为小血管炎31.0%(n=9),其中n=4例ANCA阳性。
  • 活检多取自皮肤37.9%(n=11)和肾脏24.1%(n=7)。
  • ICI方案为单药65.5%(n=19)、双药17.2%(n=5)或序贯17.2%(n=5),除1例外均含抗PD-1治疗,平均接受8.7±10.5个周期;起病平均时间7.2±7.8个月,55.2%在初始免疫治疗后>3个月起病。

关键数值与推荐

  • 血管炎分类采用2022 ACR/EULAR血管炎分类标准及2012修订版Chapel-Hill命名。
  • irAE定义借鉴Naidoo等2023年共识定义,并尝试区分激素敏感与不敏感irAE。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 数据在ICI结局(34.5%;n=10)和肿瘤结局(41.4%;n=12)方面存在缺失。
  • 作者指出亟需对血管炎等罕见irAE进行更标准化报告,以明确临床风险、分类、与免疫治疗的关系及结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/PURPOSE: Vasculitis as an immune-related adverse event (irAE) from checkpoint inhibitor therapy (ICI) to treat cancer is a rare clinical event, and little is known regarding its nosology, clinical manifestations, or response to treatment and outcomes. METHODS: To address these gaps, we used the Preferred Reporting Items for Systemic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR) framework to further define this complication. Two independent PUBMED searches in September and November of 2022 revealed 127 publications with 37 excluded from title by relevance, 43 excluded by article type, and 23 excluded due to lack of biopsy results, or biopsy negative for vasculitis. Twenty-nine documented cases from 24 publications were included for final analysis. Basic demographics, ICI details, timing of onset of vasculitis symptoms, irAE treatment and outcomes were collected. The vasculitides were classified using 2022 ACR/EULAR Vasculitis Classification Criteria as well as 2012 Revised Chapel-Hill Nomenclature. Adaptations from Naidoo et al. 2023 [1] consensus definitions for irAEs were used and efforts were made to classify steroid-responsive versus unresponsive irAEs. RESULTS: Of the 29 cases reviewed, the average age of patients was 62.1 ± 11.0, composed of 58.6 % (n = 17) male and 41.3 % (n = 12) female. Prominent cancer types were lung cancer (41.4 %; n = 12), melanoma (41.4 %; n = 12), and renal cancer (10.3 %; n = 3), with majority being stage 4 (75.9 %, n = 22) and stage 3 (10.3 %, n = 3). Only 8 cases met the ACR/EULAR criteria, and by Chapel-Hill Nomenclature, approximately a third were small-vessel vasculitis (31.0 %; n = 9) with n = 4 positive for ANCA. Most biopsies were taken from the skin (37.9 %, n = 11) and kidney (24.1 %, n = 7). Patients were either treated with single (65.5 %, n = 19), dual (17.2 %; n = 5), or sequential (17.2 %; n = 5) ICI regimen which included anti-PD-1 therapy in all but one case, with mean of 8.7 ± 10.5 cycles received. Mean time to onset of symptoms from start of ICI was 7.2 ± 7.8 months, with 55.2 % occurring >3 months since the initial immunotherapy. Vasculitis treatment included glucocorticoids in 96 % of cases and immunotherapy was often discontinued (44.8 %; n = 13). Clinical improvement of irAE was documented in 86.2 % (n = 25). Data were missing in terms of fate of ICI (34.5 %; n = 10) and tumor outcomes (41.4 %; n = 12). Cancer progressed in 20.7 % (n = 6), stable in 34.5 % (n = 10) cases, and 6 patients died of all-causes. CONCLUSION: Vasculitis as an irAE appears clinically heterogeneous and rare. Among reported cases with adequate documentation, vasculitis is of delayed onset following the initiation of immunotherapy. Outcomes of ICI-vasculitis were generally favorable, responding to glucocorticoids and immunotherapy withdrawal. There is an urgent need for more standardized reporting of rare irAEs such as vasculitis to clarify clinical risks, classification, relationship to immunotherapy and outcomes.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Lee CM, Wang M, Rajkumar A, et al. A scoping review of vasculitis as an immune-related adverse event from checkpoint inhibitor therapy of cancer: Unraveling the complexities at the intersection of immunology and vascular pathology. Semin Arthritis Rheum. 2024. PMID: 38579593. doi:10.1016/j.semarthrit.2024.152440

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。